Preoperative lifestyle intervention for breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility of a multimodal prehabilitation program for patients with breast cancer undergoing neoadjuvant chemotherapy. The program includes moderate-intensity endurance training during chemotherapy, high-intensity interval training, and strength training in the weeks leading up to surgery, along with nutritional guidance. The study aims to assess recruitment, adherence, safety, and participant acceptance, as well as evaluate preliminary effects on fitness, muscle strength, nutritional status, and fatigue. The goal is to optimize health outcomes during the preoperative period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with stage I-III breast cancer eligible for neoadjuvant intravenous chemotherapy at the MUMC+
* Aged ≥18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale grade 0-1 (Table 1)
* Enough understanding of the Dutch language

Exclusion Criteria:

* Human Epidermal growth factor Receptor 2 (HER2) - positive tumour
* Scalp cooling
* Conditions that seriously hamper physical exercise
* Incapacitated subjects as reported by the attending medical specialist in the medical record. When any doubt arises, the patient will not be considered eligible.

Where it's running

• Maastricht University Medical Center
  Maastricht, Limburg, Netherlands Recruiting

Study contacts

• Principal investigator: Hanneke Dijk - Huisman, PhD — Maastricht University Medical Center
• Study coordinator: Hanneke van Dijk - Huisman, PhD
• Email: hanneke.huisman@mumc.nl
• Phone: +31 43 3877146

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Prehabilitation plus ongoing exercise and nutrition support for women with breast cancer

  This trial will test whether a short supervised pre-treatment program of high-intensity exercise and personalized nutrition followed by home-based exercise and dietary guidance helps newly diagnosed women with stage 0–III breast cancer recover better and tolerate treatment.

  Recruiting at 2 sites European University Miguel de Cervantes · Valladolid, Valladolid and 1 other locations · NCT07467824

• HandX-assisted endoscopic nipple-sparing mastectomy (ATHENA I)

  This study tests whether a handheld robotic device called HandX can help surgeons safely perform a minimally invasive nipple-sparing mastectomy with immediate implant reconstruction for women having therapeutic or risk-reducing mastectomy.

  Recruiting Mediterraneo Hospital · Glyfada, Attica · NCT07292246

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.